Share

Collision Courses: ENDO 2021 Sessions Examined How Common Comorbidities Affected COVID-19 Patient Outcomes

Twitter_Post_ENDO_2021_Virtual Since the first, all-virtual ENDO 2021 stemmed from the lingering effects of the COVID-19 pandemic, Endocrine News presents an overview of the research that specifically addressed how the virus affects patients with common comorbidities. These studies looked at COVID-19’s effects on patients with obesity, hyperglycemia, adrenal insufficiency, and a lack of vitamin D, and provide...
Share

Inside Addition: Managing Diabetes in a Community Hospital Setting

inside addition featured Two recent papers touted the benefits of having an endocrine hospitalist-led Inpatient Diabetes Management Service (IDMS) in a community hospital setting to reduce the rates of both hypoglycemia and hyperglycemia, length of stay, and even hospital costs. Endocrine News gets a firsthand look at a community hospital’s use of an IDMS from both endocrinologists and...
Share

No Two Ways About It: Reconceptualizing Type 2 Diabetes

Drawing on years of prior research, a new paper published recently in The Journal of Clinical Endocrinology & Metabolism makes the case for a wider classification of a complex disease such as type 2 diabetes. A new series of subsets would take into account race, age at onset, and a host of other contributing factors....
Share

Phase 3 Trial Results Show Promise for Drug to Treat Severe Hypoglycemia

Earlier this week Diabetes Care published results from a Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes. Zealand Pharma is marketing the drug as Zegalogue. The study found that dasiglucagon administration resulted in a reversal of hypoglycemia (with a median recovery time of 10 minutes) with 99% of...
Share

Insulin Dosing Software Appears to Reduce Glycemic Events

Recently, Metro Health – University of Michigan Health, an affiliate of University of Michigan Health, announced that it reduced incidence of hypoglycemia by more than 54% and experienced a 40% decline in hyperglycemia since implementing personalized insulin dosing software. Glytec is marketing the software as the eGlycemic Management System® (eGMS). Extensive research links poor glycemic control...
Share

Tubeless Automated Insulin Delivery Improves Blood Glucose Outcomes

Study finds Omnipod® 5 simplifies diabetes management in type 1 diabetes People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation’s Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy. Results from an industry-sponsored study of the latest Omnipod,...